The latest update is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical Limited announced that its self-developed drug, TQB3019 (BTK PROTAC), has been approved for clinical trials by China’s National Medical Products Administration. This drug targets hematologic tumors and represents a significant advancement in overcoming BTK inhibitor resistance, with promising preclinical results showing efficacy and safety. The company is also progressing with other related drug developments, aiming to address unmet clinical needs globally.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in creating treatments for various medical needs, including cancer, using advanced technology platforms such as their OAPD® (Orally Available Protein Degrader) platform.
YTD Price Performance: 16.41%
Average Trading Volume: 1,958
Technical Sentiment Signal: Sell
Current Market Cap: $8.04B
Learn more about 1177 stock on TipRanks’ Stock Analysis page.